VentriPoint Diagnostics Ltd V.VPT

RE:RE:RE:RE:RE:Re: Bart aime ceci,Digital Twins are in the spotlight, agai

[G1945V]

Pandora wrote:

G1945V wrote:

Pandora wrote:

"RE:On Linkedin post Hugh MacNaught"

I'm not sure why an end of year letter such as this is limited to a select group on LinkedIn, as opposed to a general distribution to all shareholders.

Being the CEO he should really be doing a wider distribution -- in my opinion!. Seems you are part of the limited LinkedIn distribution. I guess that's where you get a lot of these chopped up messages.

In my opinion we whould not have to be signed up to a number of social media accounts to see what he has to say. Probably/possibly my opinion only!

"I'm not sure why an end of year letter such as this is limited to a select group on LinkedIn, as opposed to a general distribution to all shareholders."

Pandora, what end-of-the-year letter are you referring to? Is there such a letter?

Any information on this issue would be greatly appreciated.

I know that some CEOs partake in social media and stockhous-type discussions.


G1945V

It's not offically an "End of Year" letter. It is Jopatcio's post of a Hugh McNaught post on LinkedIn.

I am suggesting it sounds like an End of Year letter from the CEO and it is posted on LinkedIn which I describe as a limited distribution -- I, for one, are not a member. Maybe I am naive in my interpretation.

Here it is (I presume you have already read it under Jo's post):

Ventripoint post of Hugh MacNaught :

''My comment on our work at Ventripoint Diagnostics, and to share what we are looking ahead to in 2025.

- that will steer the company towards sales traction and growth. I am humbled to participate in this opportunity to make a meaningful difference to cardiology – both for patients and care providers. Despite a number of challenges we were able to accomplish key objectives in 2024 that include:

 ·     completing and releasing VMS+ v3.2 which features an important hardware update that users report has improved reliability and accelerated workflow

·     completing VMS+ v4 which has now received the CE mark in Europe, a Medical Device License in Canada, and has been submitted for 510(k) clearance in the United States.

·     strengthening our collaboration with ASCEND Cardiovascular in the U.S.

·     sales of systems to two of the leading cardiology centres in the U.S.

·     implementating CRM and project management platforms

·     continuing to build our commercial team

 

- By 2024 we established a new equilibrium and are positioning for sustainable growth and scale.

 

I am so thankful for the community that surrounds us every day at Ventripoint:

·     to the passionate and dedicated team who show enthusiasm and commitment to developing and commercializing our transformative technology. 

·     to our Board and Advisors, who support our work in many different ways

·     to our customers who take the time and effort to communicate and support our initiatives

·     to the many shareholders who remain engaged and supportive of our mission

 

We are looking ahead to 2025 and the opportunities that the new year will bring. Now that the key foundational elements of our technology and product development have occurred we will be introducing new options that will make it easier for customers to adopt VMS+. We are nearing the completion of updated business and operational plans and will share elements of these in early 2025.

 

Best wishes to everyone for a healthy and successful new year, and I look forward to continuing our journey to bring accurate, affordable and accessible cardiac diagnostics to communities around the world."

This was posted 2 days ago on Linkedin:

"I wanted to take a moment at the end of this eventful year to comment on our work at Ventripoint Diagnostics, and to share what we are looking ahead to in 2025. Since taking on the CEO role earlier this year my days have been occupied with meeting the many people within the Ventripoint ecosystem, reviewing innumerable documents and models, and taking the initial steps of evolving a culture within our team that will steer the company towards sales traction and growth. I am humbled to participate in this opportunity to make a meaningful difference to cardiology – both for patients and care providers. Despite a number of challenges we were able to accomplish key objectives in 2024 that include:

·     completing and releasing VMS+ v3.2 which features an important hardware update that users report has improved reliability and accelerated workflow
·     completing VMS+ v4 which has now received the CE mark in Europe, a Medical Device License in Canada, and has been submitted for 510(k) clearance in the United States.
·     strengthening our collaboration with ASCEND Cardiovascular in the U.S.
·     sales of systems to two of the leading cardiology centres in the U.S.
·     implementating CRM and project management platforms
·     continuing to build our commercial team

The global pandemic had enormous impact on companies as well as people: like many other organisations Ventripoint has had to adapt to the changes in practices and rituals of how we interact with team members, customers, and shareholders. By 2024 we established a new equilibrium and are positioning for sustainable growth and scale.

I am so thankful for the community that surrounds us every day at Ventripoint:
·     to the passionate and dedicated team who show enthusiasm and commitment to developing and commercializing our transformative technology.
·     to our Board and Advisors, who support our work in many different ways
·     to our customers who take the time and effort to communicate and support our initiatives
·     to the many shareholders who remain engaged and supportive of our mission

We are looking ahead to 2025 and the opportunities that the new year will bring. Now that the key foundational elements of our technology and product development have occurred we will focus more directly on enabling more seamless integration into clinical workflow and enhancing the user experience.
Past investments into developing market awareness are generating enquiries and we will be introducing new options that will make it easier for customers to adopt VMS+. We are nearing the completion of updated business and operational plans and will share elements of these in early 2025.

Best wishes to everyone for a healthy and successful new year, and I look forward to continuing our journey to bring accurate, affordable and accessible cardiac diagnostics to communities around the world."


G1945V